pegfilgrastim   Click here for help

GtoPdb Ligand ID: 6969

Synonyms: Neulasta®
Approved drug
pegfilgrastim is an approved drug (FDA and EMA (2002))
Compound class: Peptide or derivative
Comment: This is a PEGylated version of recombinant human G-CSF. Pegylation increases circulating half-life. In addition to pegfilgrastim, lipegfilgrastim (Lonquex®) is a glyco-PEGylated long-acting G-CSF, that is an alternative to pegfilgrastim that is clinically approved [1].

Biosimilars:
NameTrade nameCompanyClinical phaseIndications
pegfilgrastim-jmbd; MYL-1401HFulphilaMylanApproved (2018 FDA & EMA)As per reference agent [2]
 PelgrazAccordApproved (2018 EMA)As per reference agent
 PelmegMundipharma (developed by Cinfa Biotech)Approved (2018 EMA)As per reference agent
 pegfilgrastim MundipharmaMundipharma Approved (2019 EMA)As per reference agent
pegfilgrastim-cbqv; CHS-1701UdenycaERA Consulting; Coherus BioSciencesApproved (2018 FDA & EMA)As per reference agent
USV pegfilgrastimGrasustekJuta PharmaApproved (2019 EMA)As per reference agent
pegfilgrastim-bmez; LA-EP2006ZiextenzoSandozApproved (2018 EMA, 2019 FDA)As per reference agent
pegfilgrastim-apgf; PF-06881894NyvepriaPfizerApproved (2020 FDA)Indicated for neutropenia in patients undergoing cancer chemotherapy
Classification Click here for help
Compound class Peptide or derivative
Approved drug? Yes (FDA and EMA (2002))
International Nonproprietary Names Click here for help
INN number INN
8114 pegfilgrastim
Synonyms Click here for help
Neulasta®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 616
Other databases
CAS Registry No. 208265-92-3 (source: Scifinder)
ChEMBL Ligand CHEMBL1201568
DrugBank Ligand DB00019
GtoPdb PubChem SID 178103549
Search PubMed clinical trials pegfilgrastim
Search PubMed titles pegfilgrastim
Search PubMed titles/abstracts pegfilgrastim
Wikipedia Pegfilgrastim